The economic burden of supportive care of cancer patients

Abstract

Many supportive care interventions are quite expensive. In an environment focused on cost containment, a risk-based approach to expensive supportive care treatments is essential. Further study of the cost effectiveness of supportive care management strategies is indicated.

Outcomes and charges of elderly patients with acute myeloid leukemia

“…Although all are interrelated, charges tend to be higher than costs, which in turn are usually higher than reimbursements. Although some relationship exists between the three parameters, much is dependent on treatment setting, as well as the patients' insurance coverage [22,23]. Thus, the findings of any economic analysis need to be put into this framework when making comparisons to numbers found in the literature [24,25].…”

Complete prevention and rapid sustained elimination of chemoradiation toxic mucositis, a case series with implications for mucositis pathobiology, cost of care, morbidity and premature cancer deaths

“…Approximately 212,501 of them develop oropharyngeal and esophageal mucositis with an estimated 41,501 dying premature cancer deaths directly attributable to chemoradiation toxic mucositis. Besides the mortality and obvious morbidity suffered by patients, there are increased costs and resource utilization approaching $10.58 billion spent to temporize patients' medical conditions sufficiently enough for them to endure the next dose or cycle of chemoradiation [9,[20][21][22][23][24][25][26][27]. While mucositis-mediated intestinal febrile bacteremia associated with HSCT contributes 3,412 annual deaths, the remaining 38,089 deaths arise from mucositis-dependent unplanned treatment interruptions and doses reductions lower [28,29] which unavoidably lowers the "kill dose intensity" required for optimal survival and remission.…”

Oral Mucositis Results in Pediatrics Cancer Patients: Review

“…Şiddetli (evre 3-4) OM olan hastaların, şiddetli OM olmayanlara göre ortalama toplam hastane masrafları yaklaşık olarak 43.000 Dolar daha fazladır. 4,11,14,32,33 Mukozit gelişen hastaların KT esnasında hastanede yatış süresi mukoziti olmayanlara göre ortalama 8.2 gün daha fazladır. 33 Şiddetli OM olan hastalarda maliyeti hastane masrafları artırmakta-dır.…”

“…4,11,14,32,33 Mukozit gelişen hastaların KT esnasında hastanede yatış süresi mukoziti olmayanlara göre ortalama 8.2 gün daha fazladır. 33 Şiddetli OM olan hastalarda maliyeti hastane masrafları artırmakta-dır. Evre 3 ve 4'te hastanedeki maliyetin artmasının nedenleri arasında pahalı bir beslenme şekli olan parenteral beslenme, IV sıvılar, opioid kullanımı, antibakteriyel, antifungal ve antiviral ilaçların verilmesi yer almaktadır.…”